Investors / United States / AMR Action Fund
AMR Action Fund
Venture capital · Boston, MA, United States · North America
The AMR Action Fund is a venture capital fund that invests in biotechnology companies developing antimicrobial therapeutics for drug-resistant infections. It also advocates for market reforms and policy solutions aimed at changing how society values antibiotics.
Invests inHealthcare & Biotech
In its own wordsantimicrobialsantibioticsbiotechdrug resistanceglobal healththerapeutics
Your fit with AMR Action Fund
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAMR Action Fund lists 11 checked portfolio companies on its own site and is named in 5 funding rounds, 4 of them as lead. Its most frequent entry is Series A, 40% of the companies with a known first round. Its largest themes are Healthcare & Biotech (82%), Cybersecurity (9%) and AI & Machine Learning (9%). 38% of its companies are based in United States. It invests most often alongside AAF Management, Advent Life Sciences and Aisling Capital.
Counts come from funding rounds that name AMR Action Fund, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not AMR Action Fund's whole history. Rounds on record name 5 companies; its own site lists 11. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundAMR Action Fund does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 40% |
| Series B | 20% |
| Growth | 40% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 4 | 4 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 27th | 11 companies |
| Recent activity | 82th | 4 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 99th | 45% of companies confirmed by a round |
| Sector focus | 94th | 82% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| AAF Management | 1 |
| Advent Life Sciences | 1 |
| Aisling Capital | 1 |
| Astellas Venture Management | 1 |
| Brace Pharma Capital | 1 |
| Clave | 1 |
| Easton Capital | 1 |
| Founders Fund | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers11100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 82% | 15% |
| Cybersecurity | 9% | 4% |
| AI & Machine Learning | 9% | 18% |
Co-investor network
who it backs companies with, and who they back togetherCompare AMR Action Fund head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with AMR Action Fund| Date | Company | Stage |
|---|---|---|
| 6 Aug 2026 | Series C+ Led | |
| 16 Jul 2026 | Series C+ Led | |
| 1 Jul 2026 | Series A Led | |
| 24 Feb 2026 | Series A Led | |
| 16 Oct 2025 | Series B |
Round details for AMR Action Fund
Amounts, full round histories and every co-investor in AMR Action Fund's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
11 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Antabio is a clinical-stage biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens | Healthcare & Biotech | Portfolio page | ||
| BiomX Inc is now Tessera Defense and Homeland Security Inc, which provides an autonomous physical security platform | CybersecurityAI & Machine Learning | Portfolio page | ||
| BioVersys fights Antimicrobial Resistance using innovation to save lives and improve patient outcomes. | Healthcare & Biotech | Portfolio page | ||
| Centauri Therapeutics develops immunotherapies and anti-infectives for vulnerable patients | Healthcare & Biotech | Feb 2026Series A | Page + round | |
| Portfolio page | ||||
| F2G develops therapeutics for rare fungal infections | Healthcare & Biotech | Portfolio page | ||
| Pattern Bioscience develops technology for rapid and definitive identification of bacterial cells to improve antibiotic treatment | Healthcare & Biotech | Portfolio page | ||
| Peptilogics is a surgical therapeutics company that develops a novel anti-biofilm drug to cure and prevent medical device-related infections. | Healthcare & Biotech | Oct 2025Series B | Page + round | |
| Telum Therapeutics is a global drug discovery biotechnology company specializing in the use of Engineered Phage Lytic Proteins as new antimicrobial products. | Healthcare & Biotech | Jul 2026Series A | Page + round | |
| The company is developing human antibodies to break down bacterial biofilms and help antibiotics treat persistent infections. | Healthcare & Biotech | Jul 2026Series C+ | Page + round | |
| Vedanta Biosciences is advancing first-in-class Live Biotherapeutic Products to treat serious gastrointestinal diseases using defined consortia of bacteria. | Healthcare & Biotech | Aug 2026Series C+ | Page + round |
About this data
site last read 5 Nov 2026- Site
- amractionfund.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 16 Oct 2025
- Companies checked
- 11
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get AMR Action Fund's profile as data
Pull AMR Action Fund's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/amractionfund.com
# also
GET /v1/firms/amractionfund.com/portfolio
GET /v1/firms/amractionfund.com/coinvestors
GET /v1/firms/amractionfund.com/news